Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02339246 · ClinicalTrials.gov registry record · Phase 3
Pharmacokinetic Comparison Of All FK-506 Formulations
A Phase 3 study, sponsored by Veloxis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
NCT02339246 is a Phase 3 study that has completed, run by Veloxis Pharmaceuticals. The registered enrollment target is 32 participants.
The verdict
NCT02339246, a Phase 3 study, has completed, sponsored by Veloxis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the pharmacokinetic parameters of three different formulations of tacrolimus. Eligible patients will be treated with all three formulations in a pre-defined sequence.
Interventions
- DRUG Prograf vs Envarsus XR vs Astagraf XL
- DRUG Prograf vs Astagraf XL vs Envarsus XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02339246
The ClinicalTrials.gov registry entry for NCT02339246 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Veloxis Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prograf vs Envarsus XR vs Astagraf XL is the first listed.
NCT02339246 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02339246 about?
NCT02339246 is a clinical study titled "Pharmacokinetic Comparison Of All FK-506 Formulations". The purpose of the study is to compare the pharmacokinetic parameters of three different formulations of tacrolimus. Eligible patients will be treated with all three formulations in a pre-defined sequence.
What is the current status of trial NCT02339246?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2015-01. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02339246?
The interventions under investigation include: Prograf vs Envarsus XR vs Astagraf XL (DRUG), Prograf vs Astagraf XL vs Envarsus XR (DRUG).
Who is sponsoring clinical trial NCT02339246?
This trial is sponsored by Veloxis Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.